Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression

Abstract

Despite robust antitumor activity in diverse preclinical models, TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists have not demonstrated efficacy in clinical trials, underscoring the need to identify agents that enhance their activity. We postulated that the metabolic stress induced by the diabetes drug metformin would sensitize breast cancer… (More)
DOI: 10.1007/s10549-017-4201-0

Topics

3 Figures and Tables

Cite this paper

@article{Strekalova2017MetforminST, title={Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression}, author={Elena Strekalova and Dmitry Malin and Harisha Rajanala and Vincent L Cryns}, journal={Breast Cancer Research and Treatment}, year={2017}, volume={163}, pages={435-447} }